Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis

Lancet

Volumn 349, Issue 9052, 1997, Pages 589-593

  Fazekas, Franz ^a   Deisenhammer, Florian ^b   Strasser Fuchs, Siegrid ^a   Nahler, Gerhard ^c   Mamoli, Bruno ^d  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c CIS Clin Invest Support GmbH Co KG   (Austria)

^d Hospital Rosenhugel   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG THERAPY; EOSINOPHILIA; ETIOLOGY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; REMYELINIZATION;

EID: 0031057970     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09377-4     Document Type: Article

References (34)

1. Reder AT, Arnason BGW. Immunology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Handbook of clinical neurology, volume 2: demyelinating diseases. Amsterdam: Elsevier Science, 1985: 337-95.
2. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989; 10: 104-07.
3. van Der Meche FGA, Schmitz PIM, for the Dutch Guillain Barré Study Group. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-29.
4. Vermeulen M, Van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-39.
5. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegaz R. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; ii: 809.
6. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
7. Yan J, Richert JR, Sirdofsky MD. High-dose intravenous immunoglobulin for multiple sclerosis. Lancet 1990; ii: 692.
8. Rothfelder U, Neu I, Pelka R. Therapy of multiple sclerosis with immunoglobulin G. Munch Med Wochenschr 1982; 124: 74-78.
9. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22: 205-12.
10. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis: theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986; 136: 477-80.
11. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-36.
12. Weiner HL, Hafler DA. Immunotherapy of multiple sclerosis. Ann Neurol 1988; 23: 211-22.
13. Soelberg Sorensen P. Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials. J Neurol Neurosurg Psychiatry 1994; 57: S62-64.
14. Tenser RB, Hay KA, Aberg JA. Immunoglobulin G immunosuppression of multiple sclerosis: suppression of all three major lymphocyte subsets. Arch Neurol 1993; 50: 417-20.
15. Jungi TW, Breie M, Kuhnert P, et al. Effect of IgG for intravenous use on Fc receptor mediated phagocytosis by human monocytes. Clin Exp Immunol 1990; 82: 163-69.
16. Frank MM, Basta M, Fries LF. The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62: S82-86.
17. Anderson UG, Bjork L, Skansen-Saphir U, Anderson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211-16.
18. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27: 12-17.
19. van Engelen BGM, Homines OR, Pinckers A, Cruysberg JRM, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32: 835-36.
20. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994; 57: S11-14.
21. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacker KJ, Braunwald E, Wilson JD, et al, eds. Harrison's principles of internal medicine, volume 2. New York: McGraw-Hill, 1994: 2287-95.
22. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
24. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683-88.
25. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
26. Bernstein MB, Miller A, Slagle S, et al. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14.
27. Berry DA. Statistical methodology in the pharmaceutical sciences: statistics volume 104. New York: M Dekker, 1990.
28. Achiron A, Gilad R, Margalit R, et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994; 57: S57-61.
29. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
30. Jacobs DL, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
31. Miller DH, Albert PS, Barkhoff F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16.
32. van Doom PA. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1994; 57: S38-42.
33. Cherin P, Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994; 57: S50-54.
34. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-64.